<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Tian J</submitter><funding>China Postdoctoral Science Foundation</funding><funding>Science and Technology Department of Henan Province (Henan Provincial Department of Science and Technology)</funding><funding>National Natural Science Foundation of China (National Science Foundation of China)</funding><pagination>3625-3639</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12436196</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>44(38)</volume><pubmed_abstract>Centrosome amplification, a hallmark of diverse malignancies, enables cancer cell survival through centrosome clustering during mitosis, presenting a promising therapeutic target for selective elimination of cancer cells with supernumerary centrosomes. While the regulatory mechanisms underlying centrosome clustering remain poorly understood, our study identifies LIM kinase 2 (LIMK2) as a critical regulator of this process, demonstrating cancer correlation with tumor progression. Mechanistically, LIMK2 phosphorylates mammalian sterile-20-like kinase 4 (MST4) at threonine 178 (T178), activating its kinase function. Activated MST4 subsequently binds and phosphorylates nucleophosmin 1 (NPM1) at T95, a modification essential for centrosome clustering and tumor cell proliferation. Genetic deplet</pubmed_abstract><journal>Oncogene</journal><pubmed_title>LIMK2 promotes centrosome clustering and cancer progression by activating MST4-mediated phosphorylation of NPM1.</pubmed_title><pmcid>PMC12436196</pmcid><funding_grant_id>242102311218</funding_grant_id><funding_grant_id>2023M733222</funding_grant_id><funding_grant_id>8207112153</funding_grant_id><funding_grant_id>82073075</funding_grant_id><pubmed_authors>Tian J</pubmed_authors><pubmed_authors>Liu K</pubmed_authors><pubmed_authors>Song M</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Dong Z</pubmed_authors><pubmed_authors>Jia H</pubmed_authors><pubmed_authors>Yang R</pubmed_authors><pubmed_authors>Ge M</pubmed_authors><pubmed_authors>Liu S</pubmed_authors><pubmed_authors>Nie W</pubmed_authors></additional><is_claimable>false</is_claimable><name>LIMK2 promotes centrosome clustering and cancer progression by activating MST4-mediated phosphorylation of NPM1.</name><description>Centrosome amplification, a hallmark of diverse malignancies, enables cancer cell survival through centrosome clustering during mitosis, presenting a promising therapeutic target for selective elimination of cancer cells with supernumerary centrosomes. While the regulatory mechanisms underlying centrosome clustering remain poorly understood, our study identifies LIM kinase 2 (LIMK2) as a critical regulator of this process, demonstrating cancer correlation with tumor progression. Mechanistically, LIMK2 phosphorylates mammalian sterile-20-like kinase 4 (MST4) at threonine 178 (T178), activating its kinase function. Activated MST4 subsequently binds and phosphorylates nucleophosmin 1 (NPM1) at T95, a modification essential for centrosome clustering and tumor cell proliferation. Genetic deplet</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-06-03T03:02:26.092Z</modification><creation>2026-04-23T03:13:56.628Z</creation></dates><accession>S-EPMC12436196</accession><cross_references><pubmed>40775397</pubmed><doi>10.1038/s41388-025-03518-6</doi></cross_references></HashMap>